Related Experiment Videos
Praziquantel: The enigmatic antiparasitic.
T A Day1, J L Bennett, R A Pax
1Department of Pharmacology and Toxicology, Michigan State University, East Lansing, USA.
Parasitology Today (Personal Ed.)
|October 1, 1992
Summary
Praziquantel (PZQ) is a key drug for treating parasitic worm infections like schistosomiasis. However, its precise targets and mechanisms of action remain unknown, hindering further drug development.
Area of Science:
- Pharmacology
- Infectious Diseases
- Parasitology
Background:
- Praziquantel (PZQ) is the primary anthelmintic drug for human and veterinary trematode and cestode infections.
- Schistosomiasis affects an estimated 150 million people, with PZQ crucial for its control.
- Despite its widespread use since 1975, PZQ's molecular targets and mechanisms remain undefined.
Purpose of the Study:
- To review recent advancements in understanding Praziquantel's selectivity and efficacy.
- To identify the target molecules and sites of action for Praziquantel within parasites.
Main Methods:
- This review summarizes progress from various research efforts.
- Focuses on studies investigating Praziquantel's molecular interactions and effects.
Main Results:
- Recent research has made progress in elucidating Praziquantel's action.
- Key target molecules and sites of action are beginning to be identified.
Conclusions:
- Understanding Praziquantel's mechanism is vital for improving anthelmintic therapies.
- Further research is needed to fully define its targets for enhanced drug development.